BMY Bristol-Myers Squibb Company

  1. Stocks
  2. Healthcare
  3. NYSE: BMY

Price (delayed)

$56.67

Market cap

$115.76B

P/E Ratio

12.45

Dividend/share

$2.52

EPS

$4.55

Enterprise value

$150.16B

?
Relative Growth: Rel. Growth: 71
Relative Strength: Rel. Strength: 60
Relative Valuation: Rel. Valuation: 87
Relative Profitability: Rel. Profitability: 96

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Highlights
The net income has surged by 84% year-on-year and by 28% since the previous quarter
Bristol-Myers Squibb's EPS has surged by 83% YoY and by 27% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.bms.com
Peers: MRK LLY PFE NVS

Key stats

What are the main financial stats of BMY

BMY stock price

How has the Bristol-Myers Squibb stock price performed over time
Intraday
-1.58%
1 week
-4.9%
1 month
-10.95%
1 year
30.16%
YTD
5.06%
QTD
-9.18%

Financial performance

How have Bristol-Myers Squibb's revenue and profit performed over time
Revenue
$49.19B
Gross profit
$34.51B
Operating income
$11.91B
Net income
$9.28B
Gross margin
70.2%
Net margin
18.9%
The net income has surged by 84% year-on-year and by 28% since the previous quarter
The operating income has surged by 81% year-on-year and by 24% since the previous quarter
BMY's net margin has soared by 78% year-on-year and by 26% since the previous quarter
The operating margin has surged by 75% year-on-year and by 22% since the previous quarter

Price vs fundamentals

How does BMY's price correlate with its fundamentals

Growth

What is Bristol-Myers Squibb's growth rate over time

Valuation

What is Bristol-Myers Squibb stock price valuation
BMY P/E details
P/E
12.45
P/B
5.19
P/S
2.35
EV/EBIT
12.6
EV/EBITDA
9.95
EV/Sales
3.05
Bristol-Myers Squibb's EPS has surged by 83% YoY and by 27% QoQ
The stock's price to earnings (P/E) is 18% less than its last 4 quarters average of 15.1
Bristol-Myers Squibb's equity has increased by 28% YoY and by 11% from the previous quarter
BMY's P/B is 7% below its last 4 quarters average of 5.6
The price to sales (P/S) is 10% less than the 5-year quarterly average of 2.6 but 2.2% more than the last 4 quarters average of 2.3
The company's revenue rose by 3.1% YoY

Efficiency

How efficient is Bristol-Myers Squibb business performance
Bristol-Myers Squibb's ROA has soared by 91% YoY and by 30% from the previous quarter
BMY's return on invested capital has surged by 84% year-on-year and by 22% since the previous quarter
Bristol-Myers Squibb's return on sales has surged by 75% YoY and by 22% QoQ
The ROE has soared by 58% YoY and by 20% from the previous quarter

Dividends

What is BMY's dividend history
Dividend details
DPS
$2.52
Dividend yield
4.45%
Payout ratio
55.4%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Bristol-Myers Squibb financials performed over time
BMY's total assets is 34% greater than its total liabilities
The quick ratio has increased by 27% YoY and by 12% QoQ
Bristol-Myers Squibb's current ratio has increased by 26% YoY and by 8% from the previous quarter
BMY's debt is 93% greater than its equity
The company's debt to equity fell by 32% YoY and by 13% QoQ
Bristol-Myers Squibb's equity has increased by 28% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.